Researchers from Tempus partnered with Stanford University to study the genomic landscape and immunotherapy biomarkers of metastatic renal cell carcinoma (RCC) patients with and without pancreatic metastases.

Pancreatic metastases in RCC have been associated with features associated with worse response to immunotherapy. This study compared the genomic landscape and immunotherapy biomarkers of metastatic RCC patients with and without pancreatic metastases. The study found that RCC patients with pancreatic metastases have a distinct molecular profile (more prevalent ALK and NTRK3 copy number loss and less prevalent CDKN2A, BAP1, and MTAP alterations), similar MSI status and TMB, and lower rates of PD-L1 positivity, which suggests a unique disease biology and potential non-immunogenic phenotype. Further investigation is needed to determine immunotherapy outcomes in these patients. 

This study was presented at the ASCO Genitourinary Cancers Symposium 2022.